Literature DB >> 23246542

Identification of novel HLA-A 0201-restricted cytotoxic T lymphocyte epitopes from Zinc Transporter 8.

Shufa Li1, Haiying Li, Bing Chen, Debin Lu, Wuquan Deng, Youzhao Jiang, Zhongqi Zhou, Zhao Yang.   

Abstract

Numerous evidences demonstrated that type 1 diabetes (T1D) is due to a loss of immune tolerance to islet antigens, and CD8(+) T cells play an important role in the development of T1D. Zinc Transporter 8 (ZnT8) has emerged in recent years as a target of disease-associated autoreactive T cells in human T1D. However, ZnT8-associated CTL specific-peptides have not been identified. In this study, we predicted and identified HLA-A*0201-restricted cytotoxic T lymphocyte (CTL) epitopes derived from ZnT8, and utilized it to immunize HLA-A2.1/Kb transgenic (Tg) mice. The results demonstrated that peptides of ZnT8 containing residues 107-115, 115-123 and 145-153 could elicit specific CTLs in vitro, and induce diabetes in mice. The results suggest that these specific peptides are novel HLA-A*0201-restricted CTL epitopes, and could have therapeutic potential in preventing of T1D disease.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23246542     DOI: 10.1016/j.vaccine.2012.12.008

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  12 in total

1.  A subclass of serum anti-ZnT8 antibodies directed to the surface of live pancreatic β-cells.

Authors:  Chengfeng Merriman; Qiong Huang; Wei Gu; Liping Yu; Dax Fu
Journal:  J Biol Chem       Date:  2017-11-28       Impact factor: 5.157

2.  A distinct immunogenic region of glutamic acid decarboxylase 65 is naturally processed and presented by human islet cells to cytotoxic CD8 T cells.

Authors:  R R Knight; G Dolton; D Kronenberg-Versteeg; M Eichmann; M Zhao; G C Huang; K Beck; D K Cole; A K Sewell; A Skowera; M Peakman
Journal:  Clin Exp Immunol       Date:  2015-01       Impact factor: 4.330

3.  Down-regulation of the islet-specific zinc transporter-8 (ZnT8) protects human insulinoma cells against inflammatory stress.

Authors:  Chengfeng Merriman; Dax Fu
Journal:  J Biol Chem       Date:  2019-10-07       Impact factor: 5.157

4.  β-cell-specific CD8 T cell phenotype in type 1 diabetes reflects chronic autoantigen exposure.

Authors:  Ania Skowera; Kristin Ladell; David A Price; Mark Peakman; James E McLaren; Garry Dolton; Katherine K Matthews; Emma Gostick; Deborah Kronenberg-Versteeg; Martin Eichmann; Robin R Knight; Susanne Heck; Jake Powrie; Polly J Bingley; Colin M Dayan; John J Miles; Andrew K Sewell
Journal:  Diabetes       Date:  2014-09-23       Impact factor: 9.461

5.  The prevalence and predictive value of the SLC30A8 R325W polymorphism and zinc transporter 8 autoantibodies in the development of GDM and postpartum type 1 diabetes.

Authors:  Jonatan Dereke; Sanna Palmqvist; Charlotta Nilsson; Mona Landin-Olsson; Magnus Hillman
Journal:  Endocrine       Date:  2016-03-22       Impact factor: 3.633

Review 6.  Autoreactive T cells in type 1 diabetes.

Authors:  Alberto Pugliese
Journal:  J Clin Invest       Date:  2017-08-01       Impact factor: 14.808

Review 7.  Beta cell antigens in type 1 diabetes: triggers in pathogenesis and therapeutic targets.

Authors:  François-Xavier Mauvais; Julien Diana; Peter van Endert
Journal:  F1000Res       Date:  2016-04-22

8.  Identification of human leukemia antigen A*0201-restricted epitopes derived from epidermal growth factor pathway substrate number 8.

Authors:  Baishan Tang; Weijun Zhou; Jingwen Du; Yanjie He; Yuhua Li
Journal:  Mol Med Rep       Date:  2015-04-23       Impact factor: 2.952

Review 9.  Advances in the cellular immunological pathogenesis of type 1 diabetes.

Authors:  Min Li; Lu-Jun Song; Xin-Yu Qin
Journal:  J Cell Mol Med       Date:  2014-03-14       Impact factor: 5.310

Review 10.  Different role of zinc transporter 8 between type 1 diabetes mellitus and type 2 diabetes mellitus.

Authors:  Bo Yi; Gan Huang; Zhiguang Zhou
Journal:  J Diabetes Investig       Date:  2016-01-09       Impact factor: 4.232

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.